Thermo Fisher Scientific, Inc.
TMOThermo Fisher Scientific, Inc. is a global leader in scientific research and laboratory equipment, providing innovative products and services for life sciences, healthcare, and applied markets. Founded in 2006 through the merger of Thermo Electron and Fisher Scientific, the company specializes in laboratory instrumentation, analytical instruments, reagents, and consumables used in various science and clinical applications. It supports research institutions, pharmaceutical companies, and government agencies with solutions that advance scientific discovery and improve health.
Dividend History
Investors can expect a dividend payout of $0.47 per share, scheduled to be distributed in 89 days on October 15, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 15, 2026 | $0.47 | 2026-09-15 | 2026-09-15 |
| July 15, 2026 | $0.47 | 2026-06-15 | 2026-06-15 |
| April 15, 2026 | $0.47 | 2026-03-13 | 2026-03-13 |
| January 15, 2026 | $0.43 | 2025-12-15 | 2025-12-15 |
| October 15, 2025 | $0.43 | 2025-09-15 | 2025-09-15 |
Dividends Summary
- Consistent Payer: Thermo Fisher Scientific, Inc. has rewarded shareholders with 59 dividend payments over the past 14 years.
- Total Returned Value: Investors who held TMO shares during this period received a total of $14.19 per share in dividend income.
- Latest Payout: The most recent dividend of $0.47/share was paid 3 days ago, on July 15, 2026.
- Yield & Schedule: TMO currently pays dividends quarterly with an annual yield of 0.35%.
- Dividend Growth: Since 2012, the dividend payout has grown by 261.5%, from $0.13 to $0.47.
- Dividend Reliability: TMO has maintained or increased its dividend for 59 consecutive payments.
Company News
The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth a...
The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment...
The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. St...
The global biochemistry analyzer market is projected to reach $8.18 billion by 2035, driven by increasing diagnostic testing demand, adoption of fully automated systems, artificial intelligence integration, and rising preventive screening programs. The market encompasses various product types, modalities, and applications across hospitals, diagno...
The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America le...
